Philisa
            <i>FAST</i>
            ™ DNA Polymerase - Technical Note Ultra-Fast PCR using Philisa
            <i>FAST</i>
            ™ DNA Polymerase

Porter, Laura R.; Connelly, Chris M.

doi:10.2144/000114230

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Peltier devices using highly conductive materials allow with ramp rates of up to 15°C/s heating and 12°C/s cooling [86] [87]. Fast DNA polymerases, engineered with higher processing rates, extension rates, and faster activation times were used with the rapid thermal cyclers [88] . Efforts to decrease PCR times to less than 5 min were achieved by instrumentation [89] , including systems using hot and cool water for heat transfer through metal block or thin plates [90] [70] [91] and infrared-mediated temperature cycling, which enabled 3 sec PCR cycles [92].…”

Section: B Polymerase Chain Reaction (Pcr)mentioning

confidence: 99%

Navigating the Pandemic Response Life Cycle: Molecular Diagnostics and Immunoassays in the Context of COVID-19 Management

Gharizadeh

Yue

et al. 2021

IEEE Rev. Biomed. Eng.

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To counter COVID-19 spreading, an infrastructure to provide rapid and thorough molecular diagnostics and serology testing is the cornerstone of outbreak and pandemic management. We hereby review the clinical insights with regard to using molecular tests and immunoassays in the context of COVID-19 management life cycle: the preventive phase, the preparedness phase, the response phase and the recovery phase. The spatial and temporal distribution of viral RNA, antigens and antibodies during human infection is summarized to provide a biological foundation for accurate detection of the disease. We shared the lessons learned and the obstacles encountered during real world high-volume screening programs. Clinical needs are discussed to identify existing technology gaps in these tests. Leverage technologies, such as engineered polymerases, isothermal amplification, and direct amplification from complex matrices may improve the productivity of current infrastructure, while emerging technologies like CRISPR diagnostics, visual end point detection, and PCR free methods for nucleic acid sensing may lead to at-home tests. The lessons learned, and innovations spurred from the COVID-19 pandemic could upgrade our global public health infrastructure to better combat potential outbreaks in the future.

show abstract